292605-14-2
292605-14-2
Chemical Structure
SB-3CT
- CAS No.: 292605-14-2
- Formula:C15H14O3S2
- Molecular Weight:306.40
IUPAC Name: 2-(((4-phenoxyphenyl)sulfonyl)methyl)thiirane
InChIKey: LSONWRHLFZYHIN-UHFFFAOYSA-N
SMILES: O=S(CC1SC1)(C2=CC=C(OC3=CC=CC=C3)C=C2)=O
Biological Activity: SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with Ki values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
SB-3CT | 99.84% | SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with Ki values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SB-3CT (Standard) | ≥98% | SB-3CT (Standard) is the analytical standard of SB-3CT. This product is intended for research and analytical applications. SB-3CT is a potent and competitive matrix metalloproteinase MMP-2 and MMP-9 inhibitor with Ki values of 13.9 and 600 nM, respectively. SB-3CT has high selectivity for gelatinases. SB-3CT shows blood-brain barrier permeability and has neuroprotective effects and anticancer activity. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Lee M, et al. Water-Soluble MMP-9 Inhibitor Reduces Lesion Volume after Severe Traumatic Brain Injury. ACS Chem Neurosci. 2015 Oct 21;6(10):1658-64. [Content Brief]
- [2]. Stephen Brown, et al. Potent and Selective Mechanism-Based Inhibition of GelatinasesJ. Am. Chem. Soc.2000122286799-6800
- [3]. Bonfil RD, et al. Inhibition of human prostate cancer growth, osteolysis and angiogenesis in a bone metastasis model by a novel mechanism-based selective gelatinase inhibitor. Int J Cancer. 2006, 118(11), 2721-2726. [Content Brief]
